ATE408405T1 - Wässrige pharmazeutische zubereitung mit roflumilast - Google Patents
Wässrige pharmazeutische zubereitung mit roflumilastInfo
- Publication number
- ATE408405T1 ATE408405T1 AT05794694T AT05794694T ATE408405T1 AT E408405 T1 ATE408405 T1 AT E408405T1 AT 05794694 T AT05794694 T AT 05794694T AT 05794694 T AT05794694 T AT 05794694T AT E408405 T1 ATE408405 T1 AT E408405T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical preparation
- roflumilast
- aqueous pharmaceutical
- administration
- aqueous
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title 1
- 229960002586 roflumilast Drugs 0.000 title 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Farming Of Fish And Shellfish (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004046235A DE102004046235A1 (de) | 2004-09-22 | 2004-09-22 | Arzneimittelzubereitung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE408405T1 true ATE408405T1 (de) | 2008-10-15 |
Family
ID=35447576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05794694T ATE408405T1 (de) | 2004-09-22 | 2005-09-21 | Wässrige pharmazeutische zubereitung mit roflumilast |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9205044B2 (de) |
| EP (1) | EP1796668B1 (de) |
| JP (1) | JP5044404B2 (de) |
| AT (1) | ATE408405T1 (de) |
| AU (1) | AU2005286476B2 (de) |
| CA (1) | CA2580397C (de) |
| CY (1) | CY1109407T1 (de) |
| DE (2) | DE102004046235A1 (de) |
| DK (1) | DK1796668T3 (de) |
| ES (1) | ES2314718T3 (de) |
| HR (1) | HRP20080640T3 (de) |
| ME (1) | ME01050B (de) |
| PL (1) | PL1796668T3 (de) |
| PT (1) | PT1796668E (de) |
| RS (1) | RS50641B (de) |
| SI (1) | SI1796668T1 (de) |
| WO (1) | WO2006032675A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| KR20110056516A (ko) * | 2008-09-12 | 2011-05-30 | 크리티컬 파머수티컬스 리미티드 | 점막 또는 피부를 통한 치료제의 흡수 개선 |
| BRPI1010576A2 (pt) | 2009-05-11 | 2016-03-15 | Berg Biosystems Llc | métodos para tratamento de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais. |
| GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| PT2544663T (pt) * | 2010-03-12 | 2018-04-05 | Berg Llc | Formulações intravenosas de coenzima q10 (coq10) e métodos de uso da mesma |
| JP2014511393A (ja) * | 2011-03-07 | 2014-05-15 | セルジーン コーポレイション | イソインドリン化合物を用いた疾患の治療方法 |
| EP2694463B8 (de) | 2011-04-04 | 2019-10-09 | Berg LLC | Behandlung von tumoren im zentralnervensystem mit coenzym q10 |
| CN102793684B (zh) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | 罗氟司特液体制剂及其制备方法 |
| AU2012271274B2 (en) | 2011-06-17 | 2017-07-27 | Berg Llc | Inhalable pharmaceutical compositions |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| ES2888074T3 (es) | 2013-08-16 | 2021-12-30 | Univ Maastricht | Tratamiento del deterioro cognitivo con inhibidor de PDE4 |
| JP6595478B2 (ja) | 2013-09-04 | 2019-10-23 | バーグ エルエルシー | コエンザイムｑ１０の連続注入によるがんの治療方法 |
| CN105287366B (zh) * | 2014-06-18 | 2018-02-16 | 张蕊 | 一种维生素k1注射液及其制备方法 |
| US9969688B2 (en) | 2014-10-24 | 2018-05-15 | Hisamitsu Pharmaceutical Co., Inc. | Roflumilast prodrugs |
| WO2017007957A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Reduced sodium poloxamer-188 formulations and methods for use |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| JP7492918B2 (ja) | 2018-06-04 | 2024-05-30 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物 |
| KR102117525B1 (ko) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물 |
| IL295172A (en) | 2020-01-31 | 2022-09-01 | Arcutis Biotherapeutics Inc | Composition of topical roflumilest with improved administration and half-life in plasma |
| US20230102590A1 (en) * | 2020-02-03 | 2023-03-30 | Senju Pharmaceutical Co., Ltd. | Use of polyether compound |
| EP4255393B1 (de) | 2020-12-04 | 2025-05-28 | Arcutis Biotherapeutics, Inc. | Topische roflumilast-formulierung mit fungiziden eigenschaften |
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| JP2024506384A (ja) | 2021-02-10 | 2024-02-13 | イオリクス セラピューティクス，インコーポレーテッド | ロフルミラストの眼科的送達方法 |
| CA3231766A1 (en) | 2021-09-22 | 2023-03-30 | Elizabeth W. JEFFORDS | Methods of treating ocular inflammatory diseases |
| CA3242322A1 (en) | 2021-12-28 | 2023-07-06 | Arcutis Biotherapeutics, Inc. | Topical roflumilast aerosol foams |
| AU2023342481A1 (en) | 2022-09-15 | 2025-04-10 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046939C (zh) | 1993-07-02 | 1999-12-01 | 比克·古尔顿·劳姆贝尔格化学公司 | 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 |
| DK1075276T3 (da) * | 1998-05-07 | 2008-02-11 | Corixa Corp | Adjuvanssammensætning og fremgangsmåder til dens anvendelse |
| JP2002538207A (ja) | 1999-03-10 | 2002-11-12 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 多発性硬化症治療のための３−シクロプロピルメトキシ−４−ジフルオロメトキシ−ｎ−（３，５−ジクロロピリド−４−イル）ベンズアミド |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US20060084684A1 (en) * | 2002-05-28 | 2006-04-20 | Altana Pharma Ag | Topically applicable pharmaceutical preparation |
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| AR040603A1 (es) * | 2002-07-19 | 2005-04-13 | Abbott Lab S A | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos |
-
2004
- 2004-09-22 DE DE102004046235A patent/DE102004046235A1/de not_active Withdrawn
-
2005
- 2005-09-21 CA CA2580397A patent/CA2580397C/en not_active Expired - Fee Related
- 2005-09-21 DK DK05794694T patent/DK1796668T3/da active
- 2005-09-21 DE DE602005009848T patent/DE602005009848D1/de not_active Expired - Lifetime
- 2005-09-21 RS RSP-2008/0591A patent/RS50641B/sr unknown
- 2005-09-21 SI SI200530511T patent/SI1796668T1/sl unknown
- 2005-09-21 PT PT05794694T patent/PT1796668E/pt unknown
- 2005-09-21 JP JP2007531767A patent/JP5044404B2/ja not_active Expired - Fee Related
- 2005-09-21 AT AT05794694T patent/ATE408405T1/de active
- 2005-09-21 ME MEP-2008-797A patent/ME01050B/me unknown
- 2005-09-21 PL PL05794694T patent/PL1796668T3/pl unknown
- 2005-09-21 EP EP05794694A patent/EP1796668B1/de not_active Expired - Lifetime
- 2005-09-21 ES ES05794694T patent/ES2314718T3/es not_active Expired - Lifetime
- 2005-09-21 HR HR20080640T patent/HRP20080640T3/xx unknown
- 2005-09-21 AU AU2005286476A patent/AU2005286476B2/en not_active Ceased
- 2005-09-21 US US11/662,887 patent/US9205044B2/en not_active Expired - Fee Related
- 2005-09-21 WO PCT/EP2005/054723 patent/WO2006032675A1/en not_active Ceased
-
2008
- 2008-12-10 CY CY20081101429T patent/CY1109407T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ME01050B (me) | 2012-10-20 |
| RS50641B (sr) | 2010-06-30 |
| AU2005286476A1 (en) | 2006-03-30 |
| US9205044B2 (en) | 2015-12-08 |
| JP2008513416A (ja) | 2008-05-01 |
| DE602005009848D1 (de) | 2008-10-30 |
| EP1796668A1 (de) | 2007-06-20 |
| SI1796668T1 (sl) | 2009-02-28 |
| AU2005286476B2 (en) | 2011-11-10 |
| CA2580397A1 (en) | 2006-03-30 |
| JP5044404B2 (ja) | 2012-10-10 |
| CY1109407T1 (el) | 2014-07-02 |
| PT1796668E (pt) | 2008-12-22 |
| HRP20080640T3 (en) | 2009-01-31 |
| US20070259009A1 (en) | 2007-11-08 |
| DE102004046235A1 (de) | 2006-03-30 |
| WO2006032675A1 (en) | 2006-03-30 |
| EP1796668B1 (de) | 2008-09-17 |
| ES2314718T3 (es) | 2009-03-16 |
| PL1796668T3 (pl) | 2009-02-27 |
| DK1796668T3 (da) | 2009-02-02 |
| CA2580397C (en) | 2013-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE408405T1 (de) | Wässrige pharmazeutische zubereitung mit roflumilast | |
| GEP20105083B (en) | A solid pharmaceutical dosage formulation | |
| ATE403432T1 (de) | Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester- transferproteininhibitors | |
| DE60325354D1 (de) | Topisch anwendbare pharmazeutische zubereitung | |
| CY1109523T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv | |
| HN2005000039A (es) | Derivados de indazol como inhibidores de la lipasa sensible a hormonas. | |
| NO20053076D0 (no) | Farmasoytisk formulering med en uloselig aktiv forbindelse. | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| HN2002000247A (es) | Derivados de sulfonamida | |
| WO2007036952A3 (en) | Novel sustained release dosage form | |
| DE602005016532D1 (de) | Pharmazeutische zusammensetzung mit einem benzodiaeins | |
| HN2003000185A (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso. | |
| BRPI0415053A (pt) | inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| DK1641438T3 (da) | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel | |
| ATE415949T1 (de) | Pharmazeutische formulierung mit levothyroxin- natrium | |
| MXPA06011467A (es) | Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). | |
| ATE549016T1 (de) | Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe | |
| ATE401863T1 (de) | Neue viskoelastische zusammensetzung umfassend alginat und vitamin e tpgs oder tpgsa | |
| BRPI0514724A (pt) | inibidores da enzima hiv integrase | |
| NO20061088L (no) | Protonpumpe inhibitor formuleringer og fremgangsmater for fremstilling og anvendelse av slike formuleringer | |
| EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса | |
| PA8646301A1 (es) | Inhibidores de la adenilato ciclasa soluble | |
| CR8948A (es) | Composicion farmaceutica | |
| EP1652525A4 (de) | Anti-coronavirus-arzneimittel | |
| ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1796668 Country of ref document: EP |